Floatz logo

Loncastuximab Tesirine

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Fred Hutchinson Cancer Centerantibody_drug_conjugatePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Yazeed Sawalha
Phase 2B
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2B
ETOPOSIDE
David Bond, MD
Phase 2B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2B
Inno-206
Rutgers, The State University of New Jersey
Phase 2B

View all 39 →

Same molecule, other indications

Loncastuximab Tesirine is also rated in:

Refractory Diffuse Large B-Cell LymphomaDormant
B
Indicative ·
62 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
61 / 100
View asset →
Refractory B-Cell Non-Hodgkin LymphomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →